Ides in Highly Sensitized Patients Awaiting Kidney Transplantation
Status:
Completed
Trial end date:
2017-12-30
Target enrollment:
Participant gender:
Summary
IdeS® is an IgG-degrading enzyme of S.pyogenes that cleaves all four human subclasses of IgG
with strict specificity. Alloantibodies are a major deterrent to access to and success of
life-saving organ transplants. We hypothesize that the use of IdeS® pre-transplant in HS
patients will represent a more robust and complete technique to eliminate DSA from the sera
of HS patients. A single dose administration of IdeS® in the pre-operative period to HS
patients with positive DSAs and flow cytometry crossmatches will durably eliminate
circulating DSAs, allow transplantation to occur without ABMR and, in conjunction with
standard desensitization therapy, result in a durable suppression of DSA levels thus
eliminating the risk for ABMR.